PPI-668

Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668.
BusinessWire
Sun, 11/6/11 - 12:19 pm
NS5A Inhibitors
PPI-461
PPI-668
HCV